Incidence of prostate, colorectal and male breast cancers in relation with statins and testosterone replacement therapy: SEER-Medicare 2007-2015.

Autor: Abdelgadir O; Graduate School of Biomedical Science, University of Texas Medical Branch, Galveston, TX, USA., Hussain MR; School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: mrhussai@utmb.edu., Polychronopoulou E; School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA., Tsilidis KK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece., Alzweri L; Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA., Villasante-Tezanos A; School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA., Baillargeon J; School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA., Canfield S; Division of Urology, Department of Surgery, UTHealth McGovern Medical School, Houston, TX, USA., Kuo YF; School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA., Lopez DS; School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA.
Jazyk: angličtina
Zdroj: Cancer epidemiology [Cancer Epidemiol] 2024 Oct; Vol. 92, pp. 102633. Date of Electronic Publication: 2024 Aug 21.
DOI: 10.1016/j.canep.2024.102633
Abstrakt: Introduction: Statins and testosterone replacement therapy (TTh) have been inconsistently associated with a reduced risk of hormone-related cancers (HRCs, prostate [PCa], colorectal [CRC], and male breast cancers [BrCa]). Yet, the joint association of statins and TTh with the incidence of these cancers, and whether these associations vary by race, remains poorly understood. The objective of this retrospective cohort study is to examine the independent and joint effects of pre-diagnostic use of statins and TTh on the risk of HRCs, including PCa, CRC, and male BrCa.
Materials: and Methods: In 105,690 men (≥65 yrs) identified using the SEER-Medicare 2007-2015 data, we identified 82,578 White and 10,256 Black men. Pre-diagnostic prescription of statins and TTh was ascertained for this analysis and categorized into four groups (Neither users, statins alone, TTh alone and Dual users). Multivariable Time-varying Cox proportional hazards and Accelerated Failure Time (AFT) models were performed.
Results: We found inverse joint associations of statins and TTh with incident HRCs before (aHR: 0.39; 95 % CI: 0.35-0.44) and after 3 years of follow-up (aHR: 0.74; 95 % CI: 0.67-0.82). This included a lower risk for advanced stage HRC (only <3 years follow-up). Similar joint associations were identified with incident PCa, aggressive PCa, incident CRC, and its specific right- and left-sided CRC (only <3 years follow-up). In general, the inverse associations persisted among White (mainly <3 years follow-up) and Black men (high-grade HRC and <3 years follow-up). Findings from the AFT analysis were similar.
Discussion: Pre-diagnostic use of statins and TTh were, independently and jointly, associated with reduced risks of HRC and specific cancer sites at three years of follow-up overall, and among White and Black men. Greatest associations of HRCs risk reduction were observed among dual users (statins plus TTh). Further studies are needed to validate these findings, including larger samples of Black men, and male BrCa sites.
Competing Interests: Declaration of Competing Interest “The authors have no competing interests to declare that are relevant to the content of this article.” “This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.”
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: